All these genes (AP2M1, FKBP11, GALNT6, BDNF, COL9A3 and NR4A1) favor relevant features of cancer progression, indicating that their epigenetic activation in CTCs of CRC patients under treatment could be a key event for the development of therapy resistance and cancer progression. This evidence concerns the gene GALNT6 and colorectal carcinoma.